ReviewIndian journal of surgical oncology2016
Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei.
Review in Indian journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06839378 (Fluorouracil-labeled Nascent RNA Technology for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei), which is not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fluorouracil-labeled Nascent RNA Technology for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei
Who cites it
43 citing papers in PubMed, 116 citations in OpenAlex.
- Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China.BMC cancer · 2020Trial
- The Management and Prognostic Prediction of Adenocarcinoma of Appendix.Scientific reports · 2016Trial
- Pseudomyxoma peritonei presenting with pyloric obstruction: a case report.Journal of surgical case reports · 2026Article
- Review
- Low-Grade Appendiceal Mucinous Neoplasm as an Incidental Finding During Cesarean Section: A Case Report.The American journal of case reports · 2025Article
- Classic multivisceral transplant for advanced nonresectable pseudomyxoma peritonei: a case report.Journal of medical case reports · 2025Article
- Two cases of low-grade appendiceal mucinous neoplasm (LAMN) mimicking ovarian tumors successfully treated with laparoscopic surgery.Fukushima journal of medical science · 2025Article
- Low-grade appendiceal mucinous neoplasms: a case series.Journal of surgical case reports · 2025Article
- Case Report: Insights into multiple cases of Pseudomyxoma peritonei.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Article
- Pseudomyxoma retroperitonei secondary to appendiceal mucinous adenocarcinoma disguised as psoas abscess - A case report.International journal of surgery case reports · 2025Article
- Article
- Pseudomyxoma Peritonei Misdiagnosed as Liver Cirrhosis: A Case Report and Literature Review.Cureus · 2024Article
- Asymptomatic low-grade appendiceal mucinous neoplasm: A case report.World journal of clinical cases · 2024Article
- Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei.European radiology · 2023Article
- [Current treatment recommendations for pseudomyxoma peritonei].Chirurgie (Heidelberg, Germany) · 2022Review
- Rare presentation of low-grade appendiceal mucinous neoplasms (LAMN) as an appendicular lump: A case report.Annals of medicine and surgery (2012) · 2022Article
- A proposal for changing nomenclature from pseudomyxoma peritonei (PMP) to abdomino-peritoneal mucinous carcinoma (APM) based on its long journey and experience from tertiary oncology center in India.World journal of surgical oncology · 2022Article
- Inverted Appendix in a Patient With Weakness and Occult Bleeding.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022Article
- Low-grade appendiceal mucinous neoplasm (LAMN) as a mimicker of perforated diverticulitis: a case report.Journal of surgical case reports · 2022Article
- Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoplasms of the appendix are rare, but because of their unusual presentation and unpredictable biologic behavior, it is important to diagnose them correctly. Mucinous tumors account for 58 % of malignant tumors of appendix in SEER database and the remaining are carcinoids. The mucinous appendiceal tumors have a potential to spread to the peritoneum and viscera in the form of gelatinous material with or without neoplastic cells resulting in Pseudomyxoma peritonei. (PMP) PMP is a clinical entity that has a unique biological behavior and can arise from seemingly benign tumors to frankly malignant ones. Several classifications exist for PMP of which Ronnet's classification has been the most popular. In 2010, the WHO proposed a 2 tier classification that classified PMP as either low grade or high grade based on the presence of mucin, cytological and architectural features. According to this classification when the underlying cause for PMP is an appendiceal tumor it is always a mucinous adenocarcinoma rather than a mucocoele or adenoma and these terms should no longer be used. This system of classification helps in predicting the behavior of the tumor and proper treatment strategies. The understanding of the pathogenesis of the disease has also improved with identification of newer biomarkers and molecular genetic alterations. IHC markers CK 20, CDX2 and MUC2 are found to be positive in these tumors in addition to KRAS mutation and loss of heterozygosity in some gene loci. Proper histopathologic classification and predicting the tumor behavior requires a close interaction between the pathologist and the surgeon. The use of the combined modality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has led to a 5-year survival ranging from 62.5 % to 100 % for low grade, and 0 %-65 % for high grade disease. This article focuses on the etiopathogenesis, clinical behavior, diagnosis and classification of mucinous tumors of the appendix and pseudomyxoma peritonei.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.